Drug-resistant focal epilepsy remains a challenging neurological condition that significantly compromises patient independence and quality of life. Despite the historical introduction of numerous third-generation antiseizure medications, approximately one-third of individuals fail to achieve adequate seizure freedom. In this therapeutic landscape, adjunctive cenobamate provides a novel approach due to its unique dual mechanism of action. Specifically, cenobamate acts by enhancing inactivated states of voltage-gated sodium channels and positively modulating gamma-aminobutyric acid type A receptors. While randomized clinical trials established its foundational regulatory approval, prospective real-world data remain critical for clarifying practical clinical utility. Consequently, the BLESS study provides pivotal observational insights into treatment outcomes, polytherapy burden, and overall safety within routine medical practice.

Real-World Evidence for Adjunctive Cenobamate

Randomized controlled trials offer rigorous efficacy data, but they often recruit highly selected patient cohorts. In contrast, real-world observational studies capture complex patient populations with diverse comorbidities and extensive treatment histories. The BLESS study is an ongoing multicenter cohort investigation conducted across specialized Italian epilepsy centers. Researchers designed this pragmatic study to determine whether the high responder rates observed in pivotal trials translate directly to daily clinical care. Moreover, the study cohort reflects individuals with longstanding, highly refractory focal epilepsy who have exhausted multiple pharmacotherapies.

In the second interim analysis, investigators evaluated 388 adult participants who received adjunctive cenobamate. At baseline, the median participant age was 43 years, and patients had experienced a median of 7.2 monthly seizures. Most importantly, participants had previously failed a median of six distinct antiseizure medications. This extensive prior therapeutic exposure underscores the severe drug resistance present in this cohort. Consequently, demonstrating meaningful clinical improvement in such a heavily pretreated group represents a clinically robust benchmark for any emerging neurotherapeutic agent.

Key Findings of the BLESS Interim Analysis

Over the 24-week observational period, the BLESS trial recorded substantial improvements in seizure control. The median monthly seizure frequency decreased by 59.9 percent from baseline to week 24. Furthermore, 59.0 percent of participants achieved a 50 percent or greater reduction in seizure frequency, meeting the standard clinical responder threshold. In addition, 11.3 percent of patients attained complete, sustained seizure freedom throughout the maintenance timeframe. Achieving complete cessation in severe drug-resistant cohorts represents a major clinical milestone that fundamentally alters patient prognosis.

Beyond seizure reduction, investigators observed a noticeable decrease in overall antiseizure drug burden. At baseline, 56.5 percent of participants were taking two or fewer concomitant antiseizure medications. By week 24, this proportion rose to 65.7 percent, demonstrating successful de-escalation of baseline polytherapy. Clinicians frequently reduced or eliminated other medications, such as sodium channel blockers and clobazam, to prevent pharmacokinetic interactions. Therefore, adjunctive therapy with cenobamate not only suppresses epileptic activity but also facilitates rational polytherapy simplification in routine practice.

Early Versus Late Initiation of Cenobamate

A critical contribution of the BLESS interim report is the stratified subgroup analysis comparing early users against late users. Investigators defined early users as individuals who had previously failed two or three antiseizure medications. Conversely, they categorized individuals who had failed more than three medications as late users. Earlier intervention yielded markedly superior seizure control. Specifically, early users achieved a median monthly seizure reduction of 78.0 percent, compared to lower rates observed among late users. Furthermore, 76.3 percent of early users achieved at least a 50 percent reduction in seizures.

These clinical differences strongly support the hypothesis that early initiation prevents longstanding epileptogenic network reorganization. When physicians introduce effective therapies before catastrophic network remodeling occurs, therapeutic responsiveness remains considerably higher. Moreover, earlier control minimizes the cognitive and physical decline associated with years of uncontrolled seizures. Thus, clinicians should actively consider cenobamate after two appropriate medication trials fail, rather than reserving it as a final salvage option.

Safety, Tolerability, and Adverse Event Management

The safety profile observed during the BLESS study aligns closely with previous trial reports, displaying manageable adverse drug reactions. The overall frequency of adverse reactions was 5.3 percent among early users and 23.4 percent among late users. This lower incidence in early users probably reflects fewer compounding pharmacodynamic interactions from extensive baseline polytherapy. The most frequently reported adverse effects included somnolence, dizziness, and balance disorder. These central nervous system side effects typically appeared during titration phases and resolved with subsequent dose adjustment.

Importantly, 63.5 percent of participants who experienced adverse drug reactions successfully maintained their prescribed cenobamate dose. In many instances, clinicians relieved adverse symptoms by simply tapering concomitant sedating medications rather than discontinuing the study drug. Consequently, only 5.2 percent of participants permanently discontinued cenobamate therapy due to adverse events. Clinicians can maintain treatment retention by adhering strictly to the recommended slow dose titration schedule. Slow titration effectively mitigates central nervous system complaints and prevents severe immunologic cutaneous reactions.

Clinical Implications for Drug-Resistant Epilepsy

The interim findings from the BLESS study offer actionable guidance for neurologists managing treatment-resistant focal-onset seizures. Achieving substantial response rates in a cohort with a median of six failed medications highlights remarkable therapeutic potency. Furthermore, the capacity to simplify concomitant polytherapy directly benefits patients by reducing medication toxicity, sedating burdens, and systemic adverse interactions. Consequently, therapy simplification improves overall treatment adherence and enhances patient quality of life across long-term follow-up.

In clinical practice, proactive medication management remains indispensable when initiating cenobamate. Neurologists must anticipate cytochrome P450 interactions, particularly with clobazam and phenytoin, which require preemptive dose reductions. Additionally, clinicians should recognize the tangible advantages of introducing cenobamate earlier in the disease algorithm. Transitioning from sequential trial-and-error prescribing toward early, mechanism-targeted intervention may significantly lower long-term disability. Ultimately, these real-world findings establish adjunctive cenobamate as an indispensable tool in modern comprehensive epilepsy management.

Frequently Asked Questions

What makes cenobamate different from other antiseizure medications?

Cenobamate possesses an innovative dual mechanism of action. It preferentially inhibits persistent sodium currents while positively modulating gamma-aminobutyric acid type A ion channels at non-benzodiazepine binding sites. This complementary dual activity provides potent neuronal stabilization, leading to remarkable seizure control rates even in refractory focal-onset epilepsy.

Why was adverse event frequency lower in early users?

Early users had tried only two or three prior antiseizure medications, resulting in substantially fewer baseline background therapies. Consequently, these patients experienced fewer complex pharmacokinetic and pharmacodynamic drug-drug interactions. Late users frequently received higher sedative polytherapy loads, which significantly compounded central nervous system side effects like dizziness and somnolence.

How should clinicians manage concomitant medications during cenobamate titration?

Clinicians should implement proactive dosage adjustments for co-administered antiseizure medications during cenobamate titration. Cenobamate inhibits CYP2C19 and induces CYP3A4, requiring preemptive dose reductions for drugs such as clobazam, phenytoin, and carbamazepine. Proactive de-escalation of baseline therapies reduces common neurotoxic symptoms and optimizes long-term treatment retention.

Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding medical conditions. Medical knowledge is constantly evolving; therefore, readers should corroborate the information with other medical literature and professional consensus. Do not disregard or delay seeking formal medical guidance based on this content. Refer to the latest local and national guidelines for clinical practice.

References

Lattanzi S et al. Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: Interim results after 24-week observational period from the BLESS study. Epilepsia. 2025 Jul. doi: 10.1111/epi.18357. PMID: 40088187.

Sander JW et al. Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program. Epilepsia. 2022;63(1):139-149.

French JA et al. Adjunctive cenobamate for uncontrolled focal seizures: A randomized, double-blind, placebo-controlled, dose-response study. Lancet Neurol. 2020;19(1):38-48.